Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy
The DOI matches its Crossref record.
Abstract
Long term treatment with antiepileptic drugs (AEDs) is the standard therapeutic approach to eradicate seizures. However, a small but significant number of patients fail AED treatment. Intrinsic drug resistance may depend on two main and not necessarily mutually exclusive mechanisms: 1) Loss of pharmacological target (e.g., GABAA receptors); 2) poor penetration of the drug into the central nervous system (CNS). The latter is due to the action of multiple drug resistance proteins capable of active CNS extrusion of drugs. These include MDR1 (P-glycoprotein, PgP), the multidrug resistance related proteins MRP1-5, and lung-resistance protein (LRP). Overexpression of MDR1 occurs in human epileptic brain. It has therefore been proposed that MDR1/PgP may contribute to multiple drug resistance in epilepsy. In addition to MDR1/PgP, other genes such as MRP2, MRP5, and human cisplatin resistance-associated protein are also overexpressed in drug-resistant epilepsy. In normal brain tissue MDR1/PgP is expressed almost exclusively by endothelial cells (EC), while in epileptic cortex both EC and perivascular astrocytes express MDR1/PgP. The underlying causes for tissue differences may be genomic (i.e., at the DNA level), or MDR1/PgP could be induced by seizures, previous drug treatment, or a combination of the above. We will present evidence showing that expression of multiple drug resistance genes in epilepsy is a complex phenomenon and that glial cells are involved. This second line of defense for xenobiotics may have profound implications for the pharmacokinetic properties of antiepileptic drugs and their capacity to reach neuronal targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Self-citationStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
“Abbott et al., 2002 Marroni et al., 2003 Lazarowski et al., 2007 Brain tumours Breakdown of the BBB. Downregulation of tight junction protein claudin 3; redistribution of astrocyte AQP4 and Kir4.”
BackgroundSelf-citationModern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms
Schmidt, D., & Löscher, W. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.54904.x · Cited by 482
Dynamics of CNS Barriers: Evolution, Differentiation, and Modulation
Abbott, N. J. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1374-y · Cited by 469
Self-citationThe Blood–Brain Barrier and Epilepsy
Oby, E., & Janigro, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00817.x · Cited by 388
Self-citationIn Vitro Blood–Brain Barrier Models: Current and Perspective Technologies
Naik, P., & Cucullo, L. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23022 · Cited by 288
Self-citationCell–cell Signaling in the Neurovascular Unit
Lok, J., Gupta, P., Guo, S., Kim, W. J., Whalen, M. J., van Leyen, K., & Lo, E. H. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9342-9 · Cited by 242
“epilepsy, there is transient BBB opening in epileptogenic foci, and upregulated expression of P-glycoprotein and other drug efflux transporters in astrocytes and endothelium [1, 75, 76].”
BackgroundMinich, T., Riemer, J., Schulz, J. B., Wielinga, P., Wijnholds, J., & Dringen, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03737.x · Cited by 185
Cucullo, L., Hossain, M., Rapp, E., Manders, T., Marchi, N., & Janigro, D. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.00960.x · Cited by 162
Self-citationAstrocytic transporters in Alzheimer's disease
Ugbode, C., Hu, Y., Whalley, B., Peers, C., Rattray, M., & Dallas, M. L. (2017) · Biochemical Journal · doi:10.1042/bcj20160505 · Cited by 25
Metadata
- Authors
- Marroni, M., Marchi, N., Cucullo, L., Abbott, N., Signorelli, K., & Janigro, D.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 4
- Pages
- 297-304
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2121802598
- Cited by
- 81
- References
- 0
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.